BPC-157 & TB-500: The Wolverine Stack Explained

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: July 9, 2026

Key Takeaways for the Wolverine Stack

• BPC-157 and TB-500 are experimental peptides often combined as the “Wolverine Stack” to support systemic inflammation control and soft-tissue repair through complementary biological pathways.
• Preclinical animal studies show promising results for angiogenesis, collagen remodeling, and faster healing, but large-scale human trials are still lacking, so medical supervision remains essential.¹
• Supervised dosing usually involves daily BPC-157 injections and weekly TB-500 administration, with 4–8 week cycles and strict requirements for lab monitoring and high-quality sourcing.
• Contraindications include active cancer, autoimmune disease, pregnancy, and compromised liver or kidney function, so thorough screening and ongoing monitoring are required before and during therapy.
• Patients interested in personalized peptide protocols can schedule a peptide consultation with Ellie for lab-guided care tailored to their recovery goals.

BPC-157 + TB-500: How the Stack Supports Healing

BPC-157 is a 15-amino-acid synthetic fragment derived from a protective protein found in human gastric juice. It stimulates growth factors VEGF and FGF to promote angiogenesis, modulates nitric oxide to improve blood flow to injured tissue, and regulates inflammatory cytokines. TB-500 is a synthetic version of thymosin beta-4, a peptide found in nearly all human cells. TB-500 reduces TNF-alpha production, downregulates NF-kB activation, decreases oxidative stress, and promotes organized collagen deposition with anti-fibrotic activity.

The two peptides address tissue repair through distinct but complementary pathways when used together. Studies comparing combination protocols to single-peptide therapy show consistently superior outcomes, including 30–50% faster healing, more complete tissue regeneration, reduced inflammation, and improved patient-reported outcomes.¹ A 2003 study by Sikiric et al. in the Journal of Orthopaedic Research found that BPC-157 accelerated healing of transected rat Achilles tendon and improved mechanical strength of the repair.¹

The overwhelming majority of this evidence comes from animal models. A 2025 systematic review by Vasireddi et al. in HSS Journal synthesized 36 studies published between 1993 and June 2024 and documented zero completed controlled human efficacy trials for BPC-157. Large-scale human trials remain necessary before clinicians can draw definitive conclusions, yet supervised protocols have still emerged based on animal data and early clinical experience, which makes medical oversight critical.

Typical Dosing Ranges Under Supervision

BPC-157 is usually dosed at 200–500 mcg daily by subcutaneous or intramuscular injection, with weight-based guidance of approximately 2.5–10 mcg per kilogram of body weight. TB-500 in the Wolverine Stack often follows a loading phase of 2 mg twice per week for weeks 1–4, followed by a maintenance phase of 2 mg once per week.

Typical BPC-157 cycle lengths range from 4–8 weeks, and the optimal duration depends on the condition being treated. Acute injuries may respond to shorter 4-week cycles with 2–4 week rest periods. Chronic conditions often require longer continuous protocols under guidance. Because optimal dosing, route of administration, and treatment duration have not been established through clinical trials, this variability makes individualized, provider-guided protocols essential rather than optional.

Schedule your dosing consultation to receive a protocol calibrated to your lab results, health history, and recovery goals.

Safe Administration: Separate Syringes and Storage

Pre-mixed Wolverine Blend vials compounded at concentrations of 1.66 mg/ml BPC-157 and 3.33 mg/ml TB-500 are available from licensed 503A compounding pharmacies, although the regulatory landscape for this type of compounding has shifted significantly. When peptides are administered separately, they must never be drawn into the same syringe, because cross-contamination can degrade peptide stability and alter dosing accuracy.

BPC-157 is administered using a 29–31 gauge insulin syringe at a 45-degree angle into pinched skin near the target area. The injection is given slowly over 10–15 seconds, with sites rotated within a 2-inch radius. Reconstituted peptide must be stored at 36–46°F and used within 30 days. Patients receive detailed reconstitution and self-administration instructions, often with video demonstrations, as part of the concierge support model.

Lab Monitoring for Safe Peptide Use

Medically supervised peptide therapy begins with a comprehensive lab panel. Depending on the patient’s goals and health history, this may include thyroid markers, liver and kidney function, diabetes markers, hormone panels, and inflammatory markers. These baseline results guide protocol design and serve as reference points for ongoing monitoring.

Supervised peptide therapy protocols for BPC-157 and TB-500 require a thorough initial consultation assessing health history and current medications, baseline blood panels, clear informed consent regarding the experimental nature of the therapies, and regular review appointments to monitor for adverse effects. Ellie Pranckevicius reviews all lab results directly with each patient and adjusts protocols as data evolves.

Cancer Risk, Contraindications, and Screening

Both BPC-157 and TB-500 encourage angiogenesis and cell proliferation, creating a theoretical though unproven risk in humans that long-term or high-dose use could stimulate growth in existing malignant or pre-malignant cells. The Wolverine Stack is contraindicated in patients with active cancer or cancer history due to growth factor upregulation, autoimmune disease where immune modulation carries additional risk, pregnancy or breastfeeding, or compromised liver or kidney function.

Pre-therapy cancer screening and a full medication review form the core of the intake process and directly shape contraindication decisions. Interactions between BPC-157/TB-500 and anticoagulants, NSAIDs, immunosuppressants, psychiatric medications, and other pharmaceutical agents are possible but largely unexplored, so a complete medication and supplement review is required before starting any protocol.

Glow Stack for Inflammation and Skin Health

The Glow Stack combines GHK-Cu, BPC-157, and TB-500 for patients whose goals extend beyond musculoskeletal repair to systemic inflammation reduction and aesthetic wellness. GHK-Cu influences the expression of over 4,000 human genes, activating repair-related genes while suppressing those linked to inflammation and degeneration. When layered with BPC-157’s anti-inflammatory cytokine modulation and TB-500’s anti-fibrotic collagen remodeling, the Glow Stack addresses skin, hair, nail, and systemic health within a single coordinated protocol.

Expected Timeline: 2, 4, and 8 Weeks

Many patients notice initial improvement within 2 to 4 weeks of peptide therapy, while full benefits including reduced inflammation and improved joint mobility often develop over 6 to 12 weeks of consistent use.¹ A general timeline under supervised protocols looks like this:

• Week 2: Reduction in acute inflammation, improved sleep quality, and early signs of tissue comfort at injury sites.¹
• Week 4: Measurable improvement in mobility, reduced pain scores, and early collagen remodeling markers.¹
• Week 8: Peak expression of the benefits described earlier, with the 30–50% acceleration in healing becoming fully evident, along with sustained inflammation control and functional improvements.¹

Individual results vary based on genetics, lifestyle, injury severity, and protocol adherence. Specific outcomes are never guaranteed.

What to Expect When You Stop Therapy

Stopping BPC-157 and TB-500 therapy gradually reduces the peptides’ active effects as exogenous levels decline. The body does not retain the signaling benefits indefinitely once treatment ends. For patients managing chronic inflammation or ongoing tissue repair needs, a maintenance protocol is often recommended to help sustain results. Introducing exogenous BPC-157 or TB-500 may potentially downregulate the body’s own production of these compounds, though the extent and clinical significance of this effect remain unknown. Ellie discusses cessation planning and maintenance options during every follow-up consultation.

Daily Use of BPC-157 and TB-500

BPC-157 is typically administered daily at 200–500 mcg, with morning administration on an empty stomach supporting better absorption. TB-500 has a longer half-life and is dosed less frequently, usually twice weekly during loading and once weekly during maintenance, so daily TB-500 administration falls outside standard supervised protocols. Whether daily BPC-157 is appropriate depends on the indication, cycle phase, and individual patient profile, which are all assessed during consultation.

Liver, Kidney, and Heart Safety

A 2020 preclinical GLP safety evaluation by Xu et al. in Regulatory Toxicology and Pharmacology examined BPC-157 across mice, rats, rabbits, and dogs using repeated-dose, genotoxicity, local-irritation, and embryo-fetal protocols, and reported that the compound was well tolerated with no serious toxicity and no genotoxic signal. Early clinical trials have investigated thymosin beta-4 in cardiac repair post-myocardial infarction. Patients with compromised liver or kidney function remain contraindicated for the Wolverine Stack, and liver and kidney markers are always included in the baseline lab panel.

TB-500 and Testosterone Levels

No peer-reviewed evidence currently links TB-500 to direct modulation of testosterone levels. TB-500’s primary mechanisms involve actin regulation, cell migration, angiogenesis, and cytokine modulation, not the hypothalamic-pituitary-gonadal axis. The long-term effects of chronic use on endocrine function and hormonal regulation have not been formally investigated for either BPC-157 or TB-500, which is why hormone panels are included in monitoring protocols for patients on extended cycles.

Using the Wolverine Stack After Surgery

Peptides can accelerate tissue integration, reduce post-operative inflammation, and minimize scar tissue formation following joint replacements, ligament reconstructions, and soft tissue repairs. Post-surgical peptide protocols are integrated as a complement to procedures performed by Dr. Akash Chandawarkar, MD. A 2026 scoping review in the Journal of Orthopaedic Experience & Innovation found that BPC-157 and thymosin beta-4 derivatives modulate angiogenesis, inflammatory signaling, fibroblast migration, and collagen remodeling, offering biological plausibility for tissue repair. The same review recommends discontinuation of unregulated injectable peptides before elective surgery and heightened postoperative surveillance, a standard applied to all surgical patients considering peptide adjuncts.

Discuss your post-surgical recovery plan with Ellie to determine whether a peptide protocol fits your specific procedure and timeline.

Supervised Care vs. Unregulated Online Sources

Attribute	Supervised Protocol with Ellie	Unregulated Online Vendors
Sourcing	Peptides sourced from reputable providers with rigorous batch testing for purity and accurate dosage	Unregulated products have been found to contain endotoxins, residual solvents, and microbial agents
Lab Review	Baseline and ongoing lab panels including thyroid, liver, kidney, diabetes markers, and hormone panels reviewed by a board-certified FNP	No clinical review, so the complete adverse event profile including rare, delayed, or cumulative effects remains unknown without monitoring
Ongoing Support	Direct 24/7 access to Ellie Pranckevicius via text, with telemedicine available across the United States including Hawaii and Alaska	No medical supervision, with risks of contamination, mislabeling, incorrect dosing, or unsafe use and no practitioner oversight
Regulatory Compliance	Protocols designed within applicable regulatory frameworks, with cancer and contraindication screening performed before initiation	As of March 2026, BPC-157 and TB-500 are on the FDA’s Category 2 bulk drug substances list, and the “research use only” label does not shield buyers from FDA enforcement

Meet Your Practitioner: Ellie Pranckevicius, FNP-BC

Ellie Pranckevicius, FNP-BC, serves as the lead practitioner for peptide therapies. She holds a Master’s in Nursing from the University of South Florida and spent four years in the Neuroscience ICU at Tampa General Hospital. That experience built deep expertise in physiology, metabolic health, and complex recovery, which directly informs her peptide protocols.

Ellie also began her career at a high-end medical spa in Boston, giving her a dual perspective that bridges esthetic assessment with advanced nursing science. Her approach centers on education and transparency. She explains the physiology behind every recommendation in relatable terms and tells patients honestly when a protocol is not yet warranted for their profile. When surgical needs arise, Ellie’s work is complemented by Dr. Akash Chandawarkar, MD, a Harvard-educated physician, Johns Hopkins-trained plastic surgeon, and fellowship-trained aesthetic surgeon at Manhattan Eye Ear & Throat Hospital.

Start your personalized peptide protocol with Ellie’s lab-guided, safety-focused approach.

Frequently Asked Questions

Are BPC-157 and TB-500 FDA-approved?

Neither BPC-157 nor TB-500 is FDA-approved for any human therapeutic indication. As of 2026, both are classified as FDA 503A Category 2 bulk drug substances, which restricts their use in licensed compounding pharmacies outside of IRB-approved clinical research. This classification does not erase the scientific basis behind the peptides, because preclinical data spanning more than three decades supports their mechanisms, but it does mean that sourcing, dosing, and administration require careful medical oversight. Protocols are designed with full awareness of this regulatory landscape, and Ellie discusses the experimental nature of these therapies with every patient during the intake consultation.

What are the risks of using peptides without medical supervision?

The primary risks of obtaining BPC-157 or TB-500 from unregulated online sources include contamination with endotoxins, heavy metals, residual solvents, and microbial agents, along with incorrect dosing due to mislabeled concentrations. There is also no screening for contraindications such as cancer history, autoimmune conditions, or drug interactions. Without baseline labs, clinicians cannot determine whether a patient’s liver, kidney, or hormonal markers are suitable for peptide therapy. These risks are addressed through comprehensive intake evaluation, batch-tested sourcing, and ongoing concierge monitoring with direct access to Ellie.

Will the benefits disappear if I stop therapy?

Stopping BPC-157 and TB-500 gradually reduces their active effects over time. For patients managing chronic inflammation or ongoing tissue repair, benefits often diminish without a maintenance protocol. The timeline for this change varies by individual, the condition being treated, and the duration of the original protocol. Ellie builds cessation and maintenance planning into every protocol review so patients understand what to expect before, during, and after a cycle.

How do results vary between individuals?

Results from BPC-157 and TB-500 therapy vary widely between individuals. Genetics, baseline inflammatory markers, injury severity, lifestyle habits, diet, and adherence to the protocol all influence outcomes. This variability is the reason standardized, one-size-fits-all protocols are avoided. Every patient receives a custom stack and dosing schedule based on lab results, medical history, and specific goals, whether that involves post-injury recovery, systemic inflammation management, or post-surgical healing support.

Is the Wolverine Stack suitable for everyone?

The BPC-157 and TB-500 stack does not suit all patients. It is contraindicated in individuals with active cancer or a history of cancer, those with autoimmune conditions where immune modulation carries elevated risk, pregnant or breastfeeding individuals, and patients with compromised liver or kidney function. Athletes subject to WADA-compliant drug testing should also know that both peptides appear on the WADA Prohibited List. A thorough consultation with Ellie, including lab review and a complete medication and supplement history, is the only reliable way to determine whether the Wolverine Stack fits a given patient’s profile.

Conclusion: Tailored, Evidence-Informed Peptide Care

The BPC-157 + TB-500 Wolverine Stack represents one of the most researched experimental peptide combinations for soft-tissue repair and systemic inflammation. Preclinical data is extensive and mechanistically compelling, while human clinical evidence is still developing. The gap between promising animal data and established human efficacy is exactly where medical supervision becomes indispensable, helping patients benefit from available science while avoiding the risks of unregulated sourcing, unsupervised dosing, and missing contraindication screening.

Ellie Pranckevicius, FNP-BC, delivers a concierge, lab-guided, and individually tailored framework that matches the complexity of the Wolverine Stack. From initial consultation through ongoing support, every element of the protocol is designed around your specific physiology, goals, and safety profile.

---